• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pigment cell research >Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8
【24h】

Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8

机译：使用针对MCAM / MUC18和IL-8的完全人类抗体对黑色素瘤进行生物免疫治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metastatic melanoma is associated with high rate of patients' mortality and represents a great challenge for cancer therapies because of its notorious resistance to chemotherapeutic drugs. Considerable efforts have been made over the last 2 decades in pursuit of new treatment modalities and identification of molecular events associated with melanoma progression and development of metastases. The acquisition of the metastatic phenotype is associated with overexpression of the adhesion molecule MCAM/MUC18 and the angiogenic factor IL-8. In this review, we summarize our current knowledge on MCAM/MUC18 and IL-8, their transcriptional regulation, and their role in melanoma growth, angiogenesis and metastasis. Further, we report on the development of new fully human antibodies, anti-MCAM/MUC18 (ABX-MA1) and anti-IL-8 (ABX-IL8), and their effects on tumor growth and metastasis in animal models. Collectively, our studies suggest that ABX-MA1 and ABX-IL8 could serve as new modalities for the treatment of melanoma either alone, or in combination with conventional chemotherapy or other antitumor agents.
机译：转移性黑色素瘤与患者高死亡率相关，并且由于其对化学治疗药物的着名抵抗力，对癌症治疗提出了巨大挑战。在过去的二十年中，为寻求新的治疗方式和鉴定与黑色素瘤进展和转移发展有关的分子事件，已经做出了相当大的努力。转移表型的获得与粘附分子MCAM / MUC18和血管生成因子IL-8的过表达有关。在这篇综述中，我们总结了关于MCAM / MUC18和IL-8的当前知识，它们的转录调控以及它们在黑素瘤生长，血管生成和转移中的作用。此外，我们报告了新的完全人类抗体，抗MCAM / MUC18（ABX-MA1）和抗IL-8（ABX-IL8）的开发，以及它们在动物模型中对肿瘤生长和转移的影响。总体而言，我们的研究表明，ABX-MA1和ABX-IL8可以单独或与常规化学疗法或其他抗肿瘤药物联合使用，作为治疗黑色素瘤的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号